Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia
Disclosure of interest: Financial support for this study was provided by Alnylam Pharmaceuticals and Biogen Poster Session II - INTRACRANIAL HEMORRHAGE 02.00 - INTRACRANIAL HEMORRHAGE - 02.01 - INTRACEREBRAL HAEMORRHAGE P771 - ESOC25-495 PREHOSPITAL DETECTION OF INTRACRANIAL HEMORRHAGE USING A PORTABLE GFAP DEVICE IN PATIENTS WITH ACUTE FOCAL NEUROLOGICAL DEFICITS OR REDUCED CONSCIOUSNESS TRANSPORTED BY EMERGENCY VEHICLES Iris Voka 1 , Love-Preet Kalra 1 , Sabina Zylyftari 1 , Mastura Ganji 1 , Deepak Bos 1 , Klodiana Meci 1 , Stephan Barthelmes 1 , Gregor Lichy 2,3 , Simon Schwarzach 4 , Till Frscher 5 , Dominik Mayer 5 , Jens Pluto 5 , Timo Breining 5 , Sebastian Luger 1,6 , Christian Foerch 1,6 1 Department of Neurology, RKH Klinikum, Ludwigsburg, Germany, 2 Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, RKH Klinikum, Ludwigsburg, Germany, 3 DRF Luftrettung Stuttgart, Stuttgart, Germany, 4 DRF Luftrettung Karlsruhe, Karlsruhe, Germany, 5 DRK Rettungsdienst Ludwigsburg, Ludwigsburg, Germany, 6 Department of Neurology, University Hospital Frankfurt, Goethe-University, Frankfurt am Main, Germany Background and Aims: Intracerebral hemorrhage(ICH) requires rapid diagnosis for optimal patient outcomes
This is why our entire operation at Real Peptides is built around an unflinching commitment to purity across our full collection of peptides
In fact, the US Anti-Doping Authority says there is a concerning lack of published clinical trial data because studies appear to have been cancelled or stopped without any published conclusions
